Omega Therapeutics ( (OMGA) ) has shared an announcement.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Michelle C. Werner has resigned from Omega Therapeutics’ Board of Directors and the Nominating and Corporate Governance Committee, effective immediately. The company has also received a non-binding proposal from Mirai Bio, Inc. to take over Omega’s rights and obligations under a collaboration agreement with Novo Nordisk and related entities. This proposal involves Mirai assuming $8 million of Omega’s debt, and the company’s Board has formed a special committee to evaluate the offer and explore strategic alternatives.
More about Omega Therapeutics
Omega Therapeutics operates within the biotechnology industry, focusing on the discovery and development of epigenetic and epigenomic controllers.
YTD Price Performance: -73.32%
Average Trading Volume: 321,751
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $44.48M
For a thorough assessment of OMGA stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue